**POLIOMYELITIS**

**Poliovirus Vaccines**

Trivalent poliovirus vaccine contains all three poliovirus serotypes (types 1, 2 and 3) and is required for school attendance. In the United States only injectable inactivated trivalent polio vaccine (IPV) has been available since 2000.

In many other countries oral polio vaccine (polio drops or OPV) continues to be used. Until the end of March 2016, OPV was a combination of the three poliovirus serotypes. However, currently manufactured OPV may contain only one or two serotypes (neither contain serotype 2), and, therefore, does not meet New York State immunization requirements.

As a result, **OPV administered on or after April 1, 2016 WILL NOT BE ACCEPTED as meeting school requirements in New York, and doses of OPV should not be entered into ATS. Vaccine doses listed as “Polio”, IPV or IPOL may be entered.**

**Poliovirus Immunity**

While documentation demonstrating immunity to all three poliovirus serotypes (types 1, 2 and 3) will be accepted (entry by the Office of School Health), laboratories have stopped testing for type 2 poliovirus since early 2017. Results for only two serotypes (types 1 and 3) are not accepted as proof of immunity.

Printouts from office based electronic health records or electronic health record vaccine flow sheets that state “immune” are not accepted. A copy of the original laboratory slip with results for all three serotypes must be submitted. We do NOT recommend such serology testing. If a child is not up to date with poliovirus vaccine, vaccination is indicated.

**Meningococcal Vaccines**

Many different meningococcal vaccines are available both in the United States and elsewhere. This is because different strains or serotypes of meningococcal bacteria exist and the vaccines used in various countries protect against the common strains seen.

**Only the quadrivalent meningococcal vaccine, MenACWY, is accepted by New York City to meet the school requirement.** Any other meningococcal vaccine documentation is NOT accepted (this includes serogroup B meningococcal vaccines, Trumenba and Bexsero, which are not accepted).

This vaccine may be documented as:

 MeningACWY

 MenACWY

 MCV4

 Menactra (Sanofi Pasteur)

Menveo (GlaxoSmithKline)

 Menomune or MPSV4 (discontinued by manufacturer in 2017– Sanofi Pasteur)

For the 2018-2019 school year, the MenACWY school requirement is that all students entering:

* 7th, 8th 9th and 12th grades, or the equivalent if in an ungraded program, must have one dose of this vaccine, *and,*
* 12th grade or the equivalent if in an ungraded program, must have received a dose of this vaccine on or after age 16 years.